Receive funding for your R&D Projects!
Your partner for subsidy advice
Your partner for subsidy advice
The invention discloses an improved version of the chorionallantic membrane, for accurate quantification of metastatic cells in different organs of the chicken embryo at a high sensitivity.
The invention identifies new mutations in the TERT promoter which qualify as diagnostic and prognostic marker.
The invention describes a miRNA which interferes with glucocorticoid signalling and can therefore be used as a therapeutic target for e.g. diabesity-related metabolic disorders.
Side effects limit the radio/chemotherapeutic doses used during cancer treatment. Rocaglamide A and derivatives show strong chemo- and radioprotective efficacy, are highly specific for normal cells and do not protect p53-deficient/mutated cancer cells.
Non-ribosomal peptides (NRPs) are secondary metabolites produced by microorganisms, e.g. bacteria and fungi. Unlike ribosomal protein bio-synthesis, non-ribosomal protein synthesis (NRPS) does not require mRNA. NRPs are a promising source of functional molecules such as antibiotics. The technology allows for the identification, high-throughput screening and easy purification of engineered NRPs by optical measures.
The technology allows for direct and indirect detection of cancer tissue. It deals with a pharmaceutical compound consisting of three subdomains: (A) for specific cell surface binding to neoplastic cells, (B) for binding radiometals via a chelator domain for e.g. PET, and (C) harboring a fluorescent dye moiety for optical detection. The combination of PET tracer and optical moiety enables the surgeon to localize the tumor preoperatively via PET/CT and intraoperatively through optical detection.